Product Name:2-amino-6-methylbenzoic acid

IUPAC Name:2-amino-6-methylbenzoic acid

CAS:4389-50-8
Molecular Formula:C8H9NO2
Purity:95%+
Catalog Number:CM101793
Molecular Weight:151.17

Packing Unit Available Stock Price($) Quantity
CM101793-100g in stock NJțƙ
CM101793-500g in stock ŴȬNJ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:4389-50-8
Molecular Formula:C8H9NO2
Melting Point:-
Smiles Code:O=C(O)C1=C(C)C=CC=C1N
Density:1.254 g/cm3
Catalog Number:CM101793
Molecular Weight:151.17
Boiling Point:
MDL No:MFCD00007809
Storage:Store at 2-8°C.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Carbonyl Compounds
In organic chemistry, a carbonyl group is a functional group with the formula C=O, composed of a carbon atom double-bonded to an oxygen atom, and it is divalent at the C atom. It is common to several classes of organic compounds (such as aldehydes, ketones and carboxylic acids), as part of many larger functional groups. A compound containing a carbonyl group is often referred to as a carbonyl compound.
Tinlorafenib
The Journal of Medicinal Chemistry releases an article titled "Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer". Mutations in the BRAF gene result in MAPK pathway activation that are most commonly found in human melanomas. The BRAF V600E mutation is among the most frequent types. Present BRAF inhibitors have significantly improved treatment outcomes for patients with BRAF V600-mutant cancers. However, their effectiveness is limited by disease progression in the brain as they don’t adequately penetrate the blood-brain barrier (BBB).
Pfizer’s Tinlorafenib (formerly PF 07284890) is a highly brain-penetrant inhibitor of BRAF V600-mutant tumors, and currently in a phase 1 clinical trial (NCT04543188).